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Abstract: A new chemoenzymatic method has been developed for the synthesis of (S)- and
(R)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl) acetamide, two key synthons for the
preparation of (S)-pramipexole, an anti-Parkinson drug, and its enantiomer dexpramipexole, which
is currently under investigation for the treatment of eosinophil-associated disorders. These two
building blocks have been obtained in good yields and high enantiomeric excess (30% and >98% ee
for the R-enantiomer, and 31% and >99% ee for the S- one) through a careful optimization of the
reaction conditions, starting from the corresponding racemic mixture and using two consecutive
irreversible transesterifications, catalyzed by Candida antarctica lipase type A. Single crystal X-ray
analysis has been carried out to unambiguously define the stereochemistry of the two enantiomers,
and to explore in depth their three-dimensional features.
Keywords: chiral synthons; pramipexole; dexpramipexole; Parkinson’s disease; hypereosinophilic
syndromes; biocatalysis; asymmetric synthesis; Candida antarctica Lipase A; irreversible
transesterification; crystal structures
1. Introduction
Pramipexole is a dopamine agonist approved for the treatment of Parkinson’s disease and for
restless legs syndrome; it is marketed as dihydrochloride salt under the brand name Mirapex [1–3].
Pramipexole or 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole 1, has a stereogenic
center on C6 (Figure 1), and only the isomer (S)-1 exhibits anti-Parkinson properties. The isomer (R)-1,
also known as dexpramipexole, was studied some years ago for the treatment of ALS (amyotrophic
lateral sclerosis) [4–6]; however, despite the promising results in early clinical studies, its development
was discontinued in 2013, due to a lack of efficacy observed in a Phase 3 study [7,8]. More recently,
a reduction in the absolute eosinophil count (AEC), coincidentally detected during the ALS-related
clinical development, suggested a possible application of dexpramipexole for the treatment of
eosinophil-associated disorders [9,10].
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Figure 1. Structures of pramipexole (S)-1 and dexpramipexole (R)-1. 
The optical purity of this compound is a crucial parameter in the synthetic process, due to the 
different activities of the two enantiomers. 
Usually, the rac-1 or its precursor, the amine rac-2 (Figure 2), are resolved by fractional 
crystallization of a diastereomeric salt [11,12] or by preparative chiral high-performance liquid 
chromatography (HPLC) [13,14]. 
Taking into account the promising results of our previous experiments [15], in which a 
Saccharomyces cerevisiae-catalyzed reduction of ketone 3 (Figure 2) afforded the optically pure (R)-4 
(Figure 2), and considering the few chemoenzymatic approaches [16,17] available for the synthesis of 
pramipexole, we studied the resolution of the alcohol rac-4 by means of an enzymatic transformation. 
The enantiopure alcohol (R)-4 proved to be a useful synthon for the synthesis of (S)-1 dihydrochloride 
monohydrate, the commercial form of this active ingredient, in five steps and 21% overall yield [15]. 
The alcohols (R)-4 and (S)-4 (Figure 2) were here studied by means of single-crystal X-ray 
diffraction, which represents the best approach to unambiguously characterize chiral compounds, as 
confirmed by our successful application of this technique to the structural analysis of several optically 
active molecules [18,19]. 
 
 
Figure 2. Structures of amine rac-2, ketone 3, alcohol (R)-4 and its isomer (S)-4. 
2. Discussion and Results 
2.1. Lipase-Catalyzed Preparation of Alcohols (R)-4 and (S)-4 
Two enzyme-catalyzed preparations of the suitable synthon of (S)-1 are reported in the literature. 
In a 2006 patent [17], the enzyme-catalyzed resolution of diamine rac-2 was described: among the 
screened enzymes, only Candida antarctica lipase A (CAL-A), under acylation conditions, and some 
lipases from Pseudomonas sp. afforded promising results (100% ee determined by HPLC analysis of 
the non-isolated diamine 2 or the corresponding amide 5) (Scheme 1A). The 2-acetylamino-4,5,6,7-
tetrahydrobenzothiazole-6-carboxylic acid 7 was resolved in 2007 by Riva et al. through a CAL-B-
catalyzed hydrolysis of the corresponding ester, affording the optically pure ester (S)-6 (by HPLC 
analysis) at 55% conversion [16] (Scheme 1, B). The (S)-acid can be converted into (S)-1 through a 
rearrangement, described in a 2005 patent [20]. 
Figure 1. Structures of pra ipexole (S)-1 and dexpra ipexole (R)-1.
The optical purity of this compound is a crucial parameter in the synthetic process, due to the
different activities of the two enantiomers.
Usually, the rac-1 or its precursor, the amine rac-2 (Figure 2), are resolved by fractional crystallization
of a diastereomeric salt [11,12] or by preparative chiral high-performance liquid chromatography
(HPLC) [13,14].
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i r . tr ct r s f i rac- , t , lc l ( )- its is r ( )- .
Taking into account the promising results of our previous experiments [15], in which a Saccharomyces
cerevisiae-catalyzed reduction of ketone 3 (Figure 2) afforded the optically pure (R)-4 (Figure 2), and
considering the few chemoenzymatic approaches [16,17] available for the synthesis of pramipexole, we
studied the resolution of the alcohol rac-4 by means of an enzymatic transformation. The enantiopure
alcohol (R)-4 proved to be a useful synthon for the synthesis of (S)-1 dihydrochloride monohydrate,
the commercial form of this active ingredient, in five steps and 21% overall yield [15].
The alcohols (R)-4 and (S)-4 (Figure 2) were here studied by means of single-crystal X-ray
diffraction, which represents the best approach to unambiguously characterize chiral compounds, as
confirmed by our successful application of this technique to the structural analysis of several optically
active molecules [18,19].
.
. . i se- t l e re r ti f lc ls ( )- ( )-
- t l r arations f t it l t f ( )- r r rt i t lit r t r .
I 006 patent [17], the enzyme-catalyzed resolution of diamine rac-2 was described: among
the screened enzymes, only Candida antarctica lipase (CAL-A), under acylati co itions,
and some lipases fr m Pseudomonas sp. afford d promising results (100% ee determined by
HPLC analysis of the non-isolated diami e 2 or the corresponding amid 5) (Sche e 1A). The
2-acet lamino-4,5,6,7-tetrahydr benzothiazole-6-carboxylic acid 7 was resolved in 2007 by Riva et al.
through a CAL-B-catalyzed hydrolysis of the corresponding ester, affording th optically pure ester
(S)-6 (by HPLC analysis) at 55% conversion [16] (Scheme 1B). The (S)-acid can be converted into (S)-1
through a rearrangement, described in a 2005 patent [20].
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In 2014, we prepared the alcohol (R)-4 in 79% yield and >98% ee from the 6-ketone 3 by means 
of a bio-reduction catalyzed by Saccharomyces cerevisiae, common baker’s yeast [15]. This synthon was 
used as a suitable precursor of (S)-1; the same (R)-4 was also used as starting material for the synthesis 
of (R)-1, after an inversion of configuration carried out through a Mitsunobu reaction, unfortunately 
characterized by a tedious purification process and low yield (27%) (Scheme 2). 
  
Scheme 2. i) Baker’s yeast, pH 7 buffer, heptane, 79%, >98% ee; ii) PhCOOH, diethyl azodicarboxylate 
(DEAD), Ph3P, DMF; iii) 1% NaOH, methanol [15]. 
Once the suitable enzyme has been identified, the well-known advantage [21–23] offered by an 
enzymatic kinetic resolution of a racemic alcohol is the obtainment of both enantiomers as optically 
pure substances, while the reduction of a ketone catalyzed by a microorganism, including 
Saccharomyces cerevisiae [15], affords only one enantiomer. The 6-hydroxy derivative of the 2-
aminotetrahydrobenzothiazole, compound 8 [15], could be a substrate of a hydrolytic enzyme, but 
preliminary attempts of resolution by means of common lipases resulted in a concurrent acylation of 
the 6-hydroxyl and 2-amino groups (Scheme 3). 
Scheme 1. (A) Enzyme-catalyzed resolution of rac-2 [17]; (B) enzyme-catalyzed resolution of rac-6 [16].
In 2014, we prepared the alcohol (R)-4 in 79% yield and >98% ee from the 6-ketone 3 by means of
a bio-reduction catalyzed by Saccharomyces cerevisiae, common baker’s yeast [15]. This synthon was
used as a suitable precursor of (S)-1; the same (R)-4 was also used as starting material for the synthesis
of (R)-1, after an inversion of configuration carried out through a Mitsunobu reaction, unfortunately
characterized by a tedious purification process and low yield (27%) (Scheme 2).
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Scheme 2. (i) Baker’s yeast, pH 7 buffer, heptane, 79%, >98% ee; (ii) PhCOOH, diethyl azodicarboxylate
(DEAD), Ph3P, DMF; (iii) 1% NaOH, methanol [15].
Once the suitable enzyme has been identified, the well-known advantage [21–23] offered
by an enzymatic kinetic resolution of a racemic alcohol is the obtainment of both enantiomers
as optically pure substances, while the reduction of a ketone catalyzed by a microorganism,
including Saccharomyces cerevisiae [15], affords only one enantiomer. The 6-hydroxy derivative
of the 2-aminotetrahydrobenzothiazole, compound 8 [15], could be a substrate of a hydrolytic enzyme,
but preliminary attempts of resolution by means of common lipases resulted in a concurrent acylation
of the 6-hydroxyl and 2-amino groups (Scheme 3).
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also observed under alcoholysis conditions, prompted us to study the enzyme-catalyzed 
transesterification of alcohol rac-4. The use of trifluoroethyl butyrate as acyl donor and the lipase 
from Pseudomonas fluorescens (PFL) or CAL-A as enzymes, which emulated the reaction conditions 
reported in the 2006 patent for the resolution of rac-2 [17], did not provide encouraging results: PFL 
did not work, and CAL-A afforded a low conversion (7%) to the corresponding butyrate, showing a 
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Furthermore, the irreversible transesterification [24,25], using vinyl acetate as acyl donor and 
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Scheme 3. First attempt of enzyme-catalyzed resolution of compound 8.
Hence, a screening was carried out choosing as substrate the acetate rac-9, which is the acetyl
ester of the alcohol rac-4, obtained by the sodium borohydride-mediated reduction of ketone 3. The
most common commercially available lipases and a cross-linked preparation of the protease subtilisin
(Alcalase® CLEA) were used under hydrolytic conditions (phosphate buffer pH 7). Only the lipase
from porcine pancreas (PPL) proved to be inactive, whereas the other tested enzymes were able to
remove the acetyl group, albeit with an unsatisfactory ee (Table 1 and Scheme 4).
Table 1. Enzyme-catalyzed hydrolysis of acetate rac-9.
Entry Enzyme Time (h) Conversion a (%)
ee (%) a
Config. c of Formed 4
Acetate 9 Alcohol 4
a PPL 168 0 - - -
b PFL 312 22 - 16 R
c CAL-A 30 46 - 39 R
d CAL-B 120 54 31 b - R
e CCL 120 64 38 b - S
f AlcalaseCLEA 96 30 - 37 R
a determined by chiral high-performance liquid chromatography (HPLC) analysis. b determined after hydrolysis of
acetate. c by comparison with the data reported in Ref. [15].
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Scheme 4. Enzyme-catalyzed hydrolysis of acetate rac-9. (i) Ac2O, py; (ii) hydrolytic enzyme, pH
7 buffer.
The alcohol (R)-4 for the synthesis of (S)-1 was obtained with all the enzymes, with the exception of
the lipase from Candida cylindracea (CCL), which led to the opposite enantiomer (S)-4. The low ee, also
observed under alcoholysis conditions, prompted us to study th enzyme-catalyzed transesterification
of alco ol rac-4. The use of trifluoroethyl butyr te as acyl donor and the lipase from Pseudomonas
fluorescens (PFL) or CAL-A as enzymes, which emulated the reacti n conditions reported in the 2006
patent for th resolution of rac-2 [17], di not provide encouraging res lts: PFL did not work, an
CAL-A afforded a l w conversion (7%) to the corresp nding butyrate, showing a 43% ee.
Further re, the irreversible transesterification [24,25], using vinyl acetate as acyl d or and
t trahy rofuran (THF) as solvent, aff rded an unsatisfactory ee (Table 2 a d Scheme 5), with the
best results being observed in the case f PFL- or CAL-A-catalyzed transf rmations (68% ee f r (R)-9,
20–23% conversion).
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Table 2. Enzyme-catalyzed irreversible transesterification of alcohol rac-4 in THF.
Entry Enzyme Time (h) Conversion a (%)
ee a
Config. of Unreacted 4
Acetate 9 Alcohol 4
a AlcalaseCLEA 168 0 - - -
b Rhizopusoryzae lipase 168 0 - - -
c PPL 168 <5 - - S
d Aspergillusniger lipase 168 14 20
b S
e CAL-B 7 60 28 S
f CCL 168 20 41 b R
g PFL 73 20 68 b S
h CAL-A 168 23 68 b S
a determined by chiral HPLC analysis. b determined after hydrolysis of acetate.
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Conversiona 
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4 
a PFL Toluene 72 35 15b 9 1 S 
b CAL-A Toluene  16 62 6b 10 1 S 
c CCL Toluene 4 45 26b 20 2 R 
. - t l ze irr ersible tra sesterification of alcohol rac-4. (i) rolytic e z e,
i l t t , t tr r f r ( ).
These rather promising results encouraged us to perform a solvent screening: besides THF, rac-4
showed an appreciable solubility in acetone, methyl isobutyl ketone (MIBK), dimethyl sulfoxide, and
dimethylformamide. Among them, the choice was addressed to the two less hydrophilic options, namely
MIBK and acetone. Moreover, toluene was selected to study the outcome of the enzyme-catalyzed
transesterification when carried out in a hydrophobic solvent, characterized by a lesser ability to strip
off the essential water from the surface of the enzymes [26], but unable to solubilize the substrate
rac-4. In this case, lipases afforded good reaction rates but a low enantioselectivity. Conversely, when
employing MIBK as solvent, moderate reaction yield and enantioselectivity were observed. In acetone,
PFL and CCL were found to be inactive, most likely due to the higher hydrophilicity of acetone
compared to MIBK; however, CAL-A showed a good enantioselectivity, albeit at the expense of the
reaction rate. To establish if the results obtained with MIBK and acetone were satisfactory for practical
purposes, the E (enantiomeric ratio) values were calculated according to Rakels et al. [27]. An enzymatic
resolution displays a preparative significance only if its E is >10 [28–31]. While the E observed in the
case of the CAL-A-catalyzed resolution in MIBK was 12, which is enough to obtain enantiomers with
ee values >98% after a second enzymatic resolution [29], the E of the CAL-A-catalyzed transformation
in acetone was 28, thus indicating the possibility to obtain more satisfactory results in terms of optical
purity and yields (Table 3).
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Table 3. Enzyme-catalyzed irreversible transesterification of rac-4 in toluene, methyl isobutyl ketone
(MIBK) and acetone.
Entry Enzyme Solvent Time (h) Conversion a (%)
ee a (%)
E c
Config. of
Unreacted 4Acetate 9 Alcohol 4
a PFL Toluene 72 35 15 b 9 1 S
b CAL-A Toluene 16 62 6 b 10 1 S
c CCL Toluene 4 45 26 b 20 2 R
d PFL MIBK 168 33 72 b 26 8 S
e CAL-A MIBK 23 64 61 b 91 12 S
f CCL MIBK 120 51 53 b 45 5 R
g PFL Acetone 168 - - - - -
h CAL-A Acetone 168 34 89 b 50 28 S
i CCL Acetone 168 - - - - -
a determined by chiral HPLC analysis. b determined after hydrolysis of acetate. c E = ln[(1 − ees)/(1 + ees/eep)]/ln[(1
+ ees)/(1 + ees/eep)].
Following the findings by Herbst, Peper, and Niemeyer [26], we also studied the possibility to
mitigate the tendency of acetone to remove the essential water molecules from the enzyme by adding
water (1 µL of distilled water/mL of acetone) or mixing it with n-hexane, with the aim of reaching a
good reaction rate together with a similar enantioselectivity to that obtained in pure acetone. The
performed tests and the obtained results are summarized in Table 4.
Table 4. CAL-A-catalyzed irreversible transesterification of rac-4 in acetone with the addition of water
or n-hexane.
Entry Solvent Time (h) Conversion a (%)
ee a (%)
E c
Acetate 9 Alcohol 4
a Acetone + 0.1%H2O
336 32 90 b 37 27
b Acetone/n-hexane1:1 32 69 47
b >99 14
c Acetone/n-hexane2:1 95 50 79
b 75 19
d Acetone/n-hexane4:1 168 45 83
b 68 22
a determined by chiral HPLC analysis. b determined after hydrolysis of acetate. c E = ln[(1 − ees)/(1 + ees/eep)]/ln[(1
+ ees)/(1 + ees/eep)].
The results reported in Table 4 show that the addition of n-hexane had a great impact on both the
enantioselectivity and the reaction rate. The higher the amount of n-hexane in the reaction medium, the
higher the reaction rate was, but at the expense of the enantioselectivity. In particular, comparing pure
acetone to the acetone/n-hexane 1:1 mixture, we observed an increase in the reaction rate (from 168 h
for a 34% conversion to 32 h for a 69% conversion) and a decrease in the enantioselectivity (the E values
changed from 28 to 14). These findings are in agreement with those reported by Herbst et al. [26]:
the conversion rate of a kinetic resolution catalyzed by a lipase decreases with a stepwise increase of
the solvent hydrophilicity (in our case with the increase of the acetone content); at the same time, the
higher the hydrophilicity of the reaction medium, the higher the enantioselectivity. This behavior can
be explained by the ability of the hydrophilic medium to extract the essential water of the enzymes,
thus lowering their activity. At the same time, an enzyme with less essential water has a highly rigid
structure, which allows it to better discriminate between the two enantiomers, leading to an increased
enantioselectivity. In this context, it is interesting to note the linear dependence between the E-value
and the amount of n-hexane in acetone, observed in the selected range (Figure 3). Moreover, the drop
in activity of CAL-A with the addition of 0.1% water to the solvent (336 h for a 32% conversion) was
previously explained by Herbst et al. [26]: under certain conditions, the addition of water can lead to
enzyme agglomeration up to denaturation.
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Figure 3. E-value versus acetone/n-hexane ratio of CAL-A-catalyzed irreversible transesterification
of rac-4.
According to the results summarized in Table 4 and Figure 3, the catalytic system employing
the mixture acetone/n-hexane 4:1 as solvent can be considered a good compromise between
enantioselectivity and reactivity, with the aim to synthesize enantiopure (R)- and (S)-4.
The first CAL-A-catalyzed transesterification was carried out starting from the racemic alcohol
rac-4. 91% ee (S)-4 and 75% ee (R)-9 were obtained (E-value of 22) at 58% conversion (about 300 h)
after chromatographic purification. The 91% ee alcohol (S)-4 was used as substrate in a second
CAL-A-catalyzed transesterification in order to obtain enantiopure (S)-4 (>99% ee at 12% conversion).
The 75% ee acetate (R)-9 was hydrolyzed to yield enantioenriched (R)-4, used as substrate in a second
CAL-A-catalyzed transesterification. This second enzymatic resolution was stopped at 78% conversion.
(R)-9 was isolated by means of chromatographic purification, affording >98% ee (R)-4 after hydrolysis.
The isolated enantiopure alcohols (S)-4 and (R)-4 show the necessary configurations for the preparation
of dexpramipexole (R)-1 and pramipexole (S)-1, according to the previously optimized method [15]
(Scheme 6).
2.2. X-ray Crystallography
The 3D structures of (R)-4 and (S)-4 were unambiguously determined by means of single-crystal
X-ray diffraction and are reported in Figure 4 as ORTEP [32] representations. Both compounds
crystallized in the monoclinic P21 space group: the asymmetric unit (ASU) of (R)-4 shows the
(R)-alcohol interacting with an ordered water molecule, while in (S)-4 the ASU accommodates two
independent molecules of the (S)-enantiomer.
Overall, the two compounds are characterized by a flat region corresponding to the thiazole ring
of the tetrahydrobenzothiazole, with the amide moiety lying on the same plane; the C9 methyl group
deviates slightly, forming an angle of 6.1(1)◦ in (R)-4, and 8.1(1)◦ and 8.8(1)◦ in (S)-4. The cyclohexene
moiety is in half-chair conformation, with the shared C2-C3 double bond belonging to the plane formed
by the heterocycle. The Cremer–Pople [33] ring puckering parameters for the six-membered ring are
QT = 0.4807(1)Å, θ = 128.9(1)◦ for (R)-4, and QT = 0.4870(1)[0.4737(1)Å], θ = 50.5(1)◦[47.4(1)] for (S)-4
(the values in the square brackets refer to the A-labeled molecule). The different θ values indicate that
the cyclohexene ring assumes opposite half-chair conformations in the two enantiomers, while the
two hydroxyl groups remain equatorially oriented in both structures. Moreover, the puckering data
evidence small differences in the shape of the cyclohexenes in (S)-4, which justifies the presence of two
distinct molecules in the crystal ASU. The superposition of the two forms of (S)-4 is shown in Figure 5,
which reveals that their most significant structural difference is represented by the torsion angles ε (ε =
H1-O1-C5-C6) involving the hydroxyl group, which are 66.7(1)◦ and 27.1(1)◦.
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Figure 5. Superposition of the two independent molecules of the asymmetric unit of (S)-4.
The analysis of the intermolecular contacts shows considerable differences between the two
crystals, even though hydrogen bonds remain the principal driving force in the solid-state assembly
(Figure 6). In (R)-4, four H-bonds consolidate the crystal packing, with the water playing a central
role in bridging the alcohol molecules: its oxygen interacts with the amidic hydrogen, while the two
hydrogens form contacts involving the oxygens of the hydroxyl and amide functions. Overall, the
water molecules create channels, crossing the crystal along the c axis (Figure 7). Another H-bond is
established between the hydrogen of the hydroxyl group and the nitrogen of the thiazole ring. The
crystal structure of (S)-4 is stabilized by just two hydrogen bonds, between the amidic hydrogen
and the hydroxyl oxygen, and between the alcoholic hydrogen and the C=O of the amide group.
No intermolecular interactions are observed between the two independent molecules of the ASU. A
summary of the H-bonds of (R)-4 and (S)-4 is reported in Table 5, along with a complete account of
their geometry.
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3. Materials and Methods
1. Materials and Reagent
All employed solvents and reagents were purchased from Sigma-Aldrich (Merck Life Science
S.r.l., Milano, Italy) and used without any further purification. Lipase B Candida antarctica (CAL-B,
Novozym®435, ≥10000 U/g), lipase A Candida antarctica (CAL-A, Immobead 150, 1620 U/g), lipase
from Candida rugosa (CCL, 6.54 U/mg), lipase from Pseudomonas fluorescens (PFL, 40.2 U/mg), lipase from
Aspergillus niger (194 U/mg), lipase from porcine pancreas (PPL, 23.9 U/mg) and lipase F-AP15 from
Rhizopus orizae (165 U/mg) were purchased from Sigma-Aldrich (Merck Life Science S.r.l., Milano, Italy).
The protease Alcalase CLEA (946 U/g) were purchased from CLEA Technologies (CLEA Technologies,
Delft, The Netherlands).
3.2. Instrumentation
TLC analyses were performed on silica gel 60 F254 plates, precoated with a fluorescent indicator
(Merck Life Science S.r.l., Milano, Italy), with detection by a 254 nm ultraviolet (UV) lamp. Column
chromatography purifications were performed on silica gel 60 (70–230 mesh) (Merck Life Science S.r.l.,
Milano, Italy), 1:20 w/w substrate/silica gel.
The employed HPLC unit was a Merck-Hitachi (Hitachi Ltd., Tokyo, Japan), equipped with a
UV detector model L-4250, pump system model L-6200 and a chromato-integrator model D-2500.
The column employed in the analyses was a Daicel Chiralpak IA (Daicel Group, Chiral Technologies
Europe, Illkirch Cedex, France). The dimension of the column is 250 mm × 4.6 mm, 5 µm. The elution
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was in isocratic mode with n-hexane/2-propanol 8:2. The flow rate was 0.7 mL/min. All the samples
were measured at λ = 254 nm and 25 ◦C. Representative retention times (Rt): (R)-4 10.7 min; (S)-4
15.3 min; (R)- and (S)-9 were not resolved and eluted at about 13.6 min. In order to establish the
enantiomeric excess of acetate 9, the compound was hydrolyzed with sodium hydroxide in methanol
(1% w/v) to the corresponding alcohol 4.
High-resolution mass spectra (HRMS) were recorded on Impact HDTM UHR-QqToF (Bruker
Daltonics, Billerica, MA, USA); acquisition parameters were set as follows: Funnel1 RF 400 Vpp,
Funnel2 RF 400 Vpp, Hexapole RF 600 Vpp, transfer time 95 µs, pre-pulse storage 12 µs, 40–650 m/z
window. Calibration was performed online using ESI-L Low Concentration Tuning Mix (Agilent
Technologies); the samples were dissolved in methanol at a final concentration of 0.1 µg/mL and
injected at an infusion rate of 3 µL/min. Data acquisition and analysis were accomplished with Bruker
Compass Data Analysis 4.1 software (Bruker Compass, Billerica, MA, USA).
Nuclear magnetic resonance (NMR) spectra were recorded on an AVANCE 500 spectrometer
(Bruker, Billerica, MA, USA) equipped with a 5 mm broadband inverse probe (BBI) with field z-gradient
operating at 500.13 and 125.76 MHz for 1H and 13C, respectively. NMR spectra were recorded at 300 K
in CDCl3 (isotopic enrichment 99.95%) solution. The data were collected and processed by XWIN-NMR
software (3.5, Bruker) running on a PC with Microsoft Windows 7 (Redmond, WA, USA). The samples
(10 mg), were dissolved in CDCl3 (0.75 mL) in a 5 mm NMR tube. Acquisition parameters for 1D
were as follows: 1H spectral width of 5000 Hz and 32 K data points providing a digital resolution of
ca. 0.305 Hz per point, relaxation delay 10 s; 13C spectral width of 29,412 Hz and 64 K data points
providing a digital resolution of ca. 0.898 Hz per point, relaxation delay 2 s. The experimental error in
the measured 1H-1H coupling constants was ± 0.5 Hz. Chemical shifts (δ) of the 1H NMR and 13C NMR
spectra are reported in ppm using the signal for residual solvent resonance as internal standard (1H
NMR: CDCl3 7.26 ppm; 13C NMR: CDCl3 77.0 ppm (central line)). The splitting pattern abbreviations
are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet, and bs, broad signal. For
two-dimensional experiments, Bruker microprograms using gradient selection (gs) were applied. All
two-dimensional spectra (COSY and HSQC) were acquired with 2048 data points for t2 and 256 for
t1 increments. The confirmation of the structure of compounds 9 was obtained by NMR analysis,
in particular through proton and carbon 1D-NMR spectra, as well as by 2D-NMR homo-correlation
(COSY) and hetero-correlation (HSQC) experiments.
The NMR and HRMS spectra, and the HPLC chromatograms are available in the
Supplementary Materials.
3.3. Chemistry
Compounds 4 and 8 were synthesized according to the methods previously described in Ref. [15].
3.3.1. rac-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl Acetate (rac-9)
To a solution of rac-4 (1.0 g, 4.7 mmol) in anhydrous pyridine (12 mL) acetic anhydride (0.9 mL,
9.5 mmol) was added. The reaction mixture was stirred at room temperature overnight. The reaction
progress was monitored by TLC analysis (dichloromethane/methanol 95:5). After complete conversion,
the reaction mixture was diluted with water (60 mL) and extracted with dichloromethane (3 × 30 mL).
The combined organic phases were dried over sodium sulfate and, after filtration, evaporated at
reduced pressure affording rac-9 as a white solid (1.1 g, 4.3 mmol, 91%).
Rf 0.6. 1H NMR (CDCl3, δ, ppm): 5.26 (m, 1H, H-6), 3.06 (dd, J = 16.3 e 4.8 Hz, 1H, Ha-7), 2.85–2.68
(m, 3H, Hb-7, Ha-4 e Hb-4), 2.23 (s, 3H, NHCOCH3), 2.13–1.98 (m, 2H, Ha-5 e Hb-5), 2.05 (s, 3H,
OCOCH3).
13C NMR (CDCl3, δ, ppm): 170.6 (OCOCH3), 167.6 (NHCOCH3), 157.2 (C-2), 142.1 (C-N), 119.6
(C-S), 68.7 (C-6), 28.5 (C-7), 27.4 (C-5), 23.2 (NHCOCH3), 23.0 (C-4), 21.2 (OCOCH3). HRMS (ESI) m/z:
Calcd. for C11H15N2O3S [M + H]+ 255.0803. Found 255.0796.
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3.3.2. General Procedure for Enzyme-Catalyzed Hydrolysis
rac-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl acetate (rac-9) (13 mg; 0.05 mmol) was
suspended in phosphate buffer pH 7 (5 mL) in a 10 mL glass vial followed by addition of the enzyme
(an amount corresponding to about 100 U). The mixture was shaken at 300 rpm and room temperature.
A sample of about 50 µL was collected regularly, diluted with water, and extracted with ethyl acetate.
The organic phase was concentrated under reduced pressure. The residue was dissolved in 2-propanol
(about 50 µL) and a portion (10 µL) was injected in a HPLC system equipped with a Chiralpak
IA column.
3.3.3. General Procedure for Enzyme-Catalyzed Transesterification
rac-N-(6-Hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide (rac-4) (10 mg; 0.05 mmol)
was dissolved or suspended in the organic solvent (5 mL) in a 10 mL glass vial followed by addition
of vinyl acetate (14 µL; 0.15 mmol) and the enzyme (an amount corresponding to about 100 U). The
mixture was shaken at 300 rpm and room temperature. A sample of about 50 µL was collected regularly
and concentrated under reduced pressure. The residue was dissolved in 2-propanol (about 50 µL) and
a portion (10 µL) was injected in a HPLC system equipped with a Chiralpak IA column.
3.3.4. Lipase-Catalyzed Synthesis of Enantioenriched
(S)-N-(6-Hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide [(S)-4]
To a solution of rac-4 (500 mg, 2.4 mmol) in anhydrous acetone (200 mL) and n-hexane (50 mL),
vinyl acetate (0.7 mL, 7.6 mmol) and CAL-A (3 g, 4860 U) were added sequentially. The reaction
mixture was shaken at room temperature and 300 rpm in a screw-cap flask. The reaction progress was
monitored by HPLC, equipped with a Chiralpak IA column. At 58% conversion (reaction time: about
300 h), the enzyme was removed by filtration and the solvent was evaporated at reduced pressure. The
residue was purified by silica gel column chromatography. By elution with n-hexane/ethyl acetate
6:4, acetate (R)-9 was recovered (328 mg, 54%). Elution with dichloromethane/methanol 95:5 afforded
enantioenriched (S)-4 (190 mg, 38%, 91% ee).
3.3.5. Hydrolysis of Enantioenriched (R)-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl Acetate
[(R)-9] to Enantioenriched (R)-4
A solution of 1% w/v sodium hydroxide in methanol (15 mL, 3.8 mmol) and enantioenriched (R)-9
(300 mg, 1.18 mmol), obtained from the enzyme-catalyzed resolution described in Section 3.3.4,
was stirred at room temperature. The reaction progress was monitored by TLC analysis
(dichloromethane/methanol 95:5) until starting material disappearance (2 h). The pH of the reaction
mixture was adjusted to 7 by addition of 1 M HCl and methanol was removed under reduced pressure.
Water was added (5 mL) and the obtained aqueous phase was extracted with ethyl acetate (5 × 5 mL).
The collected organic phases were dried over sodium sulfate; after filtration, the solvent was removed
at reduced pressure, affording enantioenriched (R)-4 (212 mg, 1.0 mmol, 85%) which was used directly
in the next step without any further purification. The 75% ee of enantioenriched (R)-4 was determined
by HPLC analysis on a Chiralpak IA column.
3.3.6. Lipase-Catalyzed Synthesis of Enantiopure
(S)-N-(6-Hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide [(S)-4]
To a solution of enantioenriched (S)-4 (150 mg, 0.71 mmol, 91% ee), obtained as described in
Section 3.3.4, in anhydrous acetone (60 mL) and n-hexane (15 mL), vinyl acetate (210 µL, 2.3 mmol) and
CAL-A (0.9 g, 1458 U) were sequentially added. The reaction mixture was shaken at room temperature
and 300 rpm in a screw-cap flask. The reaction progress was monitored by HPLC equipped with a
Chiralpak IA column. The reaction was stopped at 12% conversion (reaction time: about 48 h), the
enzyme was removed by filtration and the solvent was evaporated at reduced pressure. The residue
was purified by silica gel column chromatography. By elution with n-hexane/ethyl acetate 6:4, acetate
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(R)-9 was recovered (18 mg, 10%). Elution with dichloromethane/methanol 95:5 afforded enantiopure
(S)-4 (123 mg, 82%, >99% ee). The chemical-physical properties of (S)-4 were in agreement with the
reported ones [15].
3.3.7. Lipase-Catalyzed Synthesis of Enantiopure
(R)-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl Acetate [(R)-9]
To a solution of enantioenriched (R)-4 (200 mg, 0.94 mmol, 75% ee), obtained as described in
Section 3.3.5, in anhydrous acetone (80 mL) and n-hexane (20 mL), vinyl acetate (280 µL, 3.02 mmol) and
CAL-A (1.2 g, 1944 U) were added sequentially. The reaction mixture was shaken at room temperature
and 300 rpm in a screw-cap flask. The reaction progress was monitored by HPLC equipped with
a Chiralpak IA column. The reaction was stopped at 78% conversion (reaction time: about 144 h),
the enzyme was removed by filtration and the solvent was evaporated at reduced pressure. The
residue was purified by silica gel column chromatography. By elution with n-hexane/ethyl acetate 6:4,
acetate (R)-9 was recovered (174 mg, 72%,). Elution with dichloromethane/methanol 95:5 afforded
(S)-4 (30 mg, 15%).
3.3.8. Hydrolysis of Enantiopure (R)-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl Acetate
[(R)-9] to Enantiopure (R)-4
The hydrolysis of enantiopure (R)-9 (100 mg, 0.39 mmol), obtained from the enzyme-catalyzed
resolution described in Section 3.3.7, was carried out under the same conditions described in Section 3.3.5
affording enantiopure (R)-4 (74 mg, 0.35 mmol, 90%). The >98% ee of enantiopure (R)-4 was determined
by HPLC analysis on a Chiralpak IA column. The chemical-physical properties of (R)-4 were in
agreement with the reported ones [15].
3.4. X-ray Crystallography
Diffraction-quality crystals were obtained at room temperature by slow evaporation of an
ethanol/water 1:1 solution for (R)-4, and of a methanol/water 1:1 solution for (S)-4. After a week,
transparent crystals precipitated as prisms.
X-ray diffraction data for (R)-4 were collected at room temperature on a Bruker Apex II CCD
diffractometer, using graphite-monochromatized Mo-Ka X-radiation (λ = 0.71073 Å); for (S)-4, a
Bruker-Axs CCD-based three-circle diffractometer was used, working with the same X-ray source
(λ = 0.7107 Å) and environmental conditions.
The collected information was processed with the SAINT [34] software for data reduction (including
intensity integration, background, Lorentz and polarization corrections) and for the determination
of accurate unit-cell dimensions. Absorption effects were empirically evaluated by the SADABS [35]
software, and absorption correction was applied to the data. The structures were solved by direct
methods (SIR-14) [36] and completed by iterative cycles of full-matrix least squares refinement on
Fo2 and DF synthesis using SHELXL-17 [37] on the WingX.v2014.1 suite [38]. The hydrogen atoms
bonded to carbons were included at geometrically calculated positions and refined using a riding
model. CCDC entries 1994275 [(R)-4] and 1994277 [(S)-4] contain the Supplementary Crystallographic
Data for this paper.
Crystal data for (R)-4: C9H12N2O2S·H2O, Mr = 230.28 g/mol, Monoclinic, Space group P21, a =
6.5701(4) Å, b = 12.6906(7) Å, c = 6.9136(4) Å, β = 107.12(1), V = 550.90(5) Å3, Z = 2, Dcalc = 1.388 Mg/m3,
F(000) = 244, R = 0.040 for 3074 reflections with Fo > 4sig(Fo) (R = 0.048 for all 3416 unique/6449 collected
reflections), wR2 = 0.093 for reflections with Fo > 4sig(Fo) (wR2 = 0.098 for all unique reflections), T =
293(2) K, GOF = 1.156. The reflections were collected in the range 3.08◦ ≤ θ ≤ 31.64◦ (limiting indices =
−9 ≤ h ≤ 9, −17 ≤ k ≤ 18, −9 ≤ l ≤ 9) employing a 0.36 × 0.20 × 0.05 mm crystal. The residual positive
and negative electron densities in the final map were 0.357 and −0.186 Å−3.
Crystal data for (S)-4: C9H12N2O2S, Mr = 424.53 g/mol (212.27 g/mol for each molecule), monoclinic,
space group P21, a = 5.0452(3) Å, b = 13.3800(8) Å, c = 15.0609(3) Å, β = 90.04(1), V = 1016.7(1) Å3,
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Z = 2, Dcalc = 1.387 Mg/m3, F(000) = 448, R = 0.051 for 2737 reflections with Fo > 4sig(Fo) (R = 0.059
for all 3172 unique/7389 collected reflections), wR2 = 0.123 for reflections with Fo > 4sig(Fo) (wR2 =
0.128 for all unique reflections), T = 293(2) K, GOF = 1.005. The reflections were collected in the range
1.35◦ ≤ θ ≤ 24.01◦ (limiting indices = −5 ≤ h ≤ 5, −15 ≤ k ≤ 15, −17 ≤ l ≤ 17) employing a 0.25 × 0.16
× 0.03 mm crystal. The residual positive and negative electron densities in the final map were 0.357
and −0.243 Å−3.
4. Conclusions
The bicyclic compound pramipexole is a pharmacologically active substance, showing
anti-Parkinson effects only when its stereocenter has the (S)- configuration. Conversely, its (R)-
enantiomer is still under investigation to identify possible therapeutic applications. For these reasons,
we planned to prepare the optically pure synthons of (R)- and (S)-pramipexole, by means of the
enzymatic resolution of the suitable secondary alcohol. This result was achieved through a double
kinetic resolution, catalyzed by CAL-A; the reaction conditions were studied and optimized, also
considering the choice of the solvent. Starting from the racemic alcohol 4, a 4:1 v/v mixture of
acetone/n-hexane allowed us to obtain the (R)-alcohol 4 and (S)-alcohol 4 in >98% ee and >99% ee
and 30% and 31% overall yields, respectively. The single-crystal X-ray analysis of these compounds
unambiguously defined the 3D structural features of the two enantiomers and revealed a considerably
different crystal packing.
These two advanced chiral intermediates can be converted to (S)- and (R)-pramipexole following
the synthetic route previously optimized in our laboratory. A comparison between the two biocatalytic
approaches put in evidence that the previous method, consisting in the enantioselective reduction of
the suitable ketone 3 catalyzed by Saccharomyces cerevisiae, provided only the (R)-alcohol 4 in >98% ee.
The (S)- alcohol 4 was obtained, starting from the (R)- alcohol 4, through an inversion of configuration
operated by means of the Mitsunobu reaction that furnished a complex crude reaction mixture. After
a careful purification process the (S)- alcohol 4 was recovered in poor yield (27%). By contrast, the
new chemoenzymatic approach afforded both the (R)- and (S)-alcohol 4 in good yields (30% and 31%
overall yields, respectively) starting from rac-4; this is a remarkable result considering that, with an
enzymatic kinetic resolution of a racemate, the maximum theoretical yield for each enantiomer is 50%.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/10/8/941/s1,
Figure S1: 1H NMR of compound 9, Figure S2: 13C NMR of compound 9, Figure S3: COSY of compound 9,
Figure S4: HSQC of compound 9, Figure S5: HRMS of compound 9, Figure S6: MS-MS of compound 9, Figure S7:
Lipase-catalyzed synthesis of enantioenriched (S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide
[(S)-4]. HPLC analysis of the crude reaction mixture, Figure S8: Lipase-catalyzed synthesis of enantioenriched
(S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide [(S)-4]. HPLC analysis of the purified (S)-4, Figure
S9: Lipase-catalyzed synthesis of enantioenriched (S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide
[(S)-4]. HPLC analysis of the purified and hydrolyzed (R)-9, Figure S10: Lipase-catalyzed
synthesis of enantiopure (S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide [(S)-4]. HPLC
analysis of the crude reaction mixture, Figure S11: Lipase-catalyzed synthesis of enantiopure
(S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide [(S)-4]. HPLC analysis of the purified (S)-4,
Figure S12: Lipase-catalyzed synthesis of enantiopure (R)-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl acetate
[(R)-9]. HPLC analysis of the crude reaction mixture, Figure S13: Lipase-catalyzed synthesis of enantiopure
(R)-2-Acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl acetate [(R)-9]. HPLC analysis of the purified and hydrolyzed
(R)-9.
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